VerbrughH.A., KeaneW.F., HoidelJ.F.Peritoneal macrophages and opsonins: Antibacterial defense in patients undergoing chronic peritoneal dialysis.J Infect Dis1983; 147: 1018–29.
2.
LamperiS., CarozziS.Defective opsonic activity of peritoneal effluent during continuous ambulatory peritoneal dialysis (CAPD): Importance and prevention.Perit Dial Bull1986; 6: 87–92.
3.
Poole -WarrenL.A., BalletM.D., HoneP.W.Vaccination for prevention of CAPD associated staphylococcal infection: Results of a prospective multicenter clinical trial.Clin Nephrol1991; 5: 198–206.
4.
HolmesC.J., LewisS.Host defense mechanisms in the periwneal cavity of continuous peritoneal dialysis patients. 2. Humoral defenses.Perit Dial Int1991; 11: 112–7.
5.
ColesG.A., MinorsS.J., HortonJ.K., FifieldR., DaviesM.Can the risk of peritonitis be predicted for new continuous ambulawry peritoneal dialysis (CAPD) patients?Peril Diallnt1989; 9: 69–72.
6.
LamperiS., CarozziS.Immunological defenses in CAPD.Blood Purif1989; 7: 126–43.
7.
CarozziS., NasiniM.G., SchelottoC.In traperiwneal therapy with interferon-alpha in CAPD patients with relapsing bacterial peritonitis.ASAlO Trans1989; 25: 421–3.
8.
CarozziS., NasimiM.G., SchelotW.C.Ca2+ and 1,25 (OH)2D3 enhance peritoneal macrophage (PMΦ) antimicrobial functions in CAPD. In: KhannaR., No1phK.D., ProwantB.F., TwardowskiZ.J., Oreopoulos00, eds. Advances in peritoneal dialysis.Peritoneal Dialysis Bulletin, Inc.1989: 103–10.
9.
LevyR., KleinJ., RubinekT.Diversity in peritoneal macrophage response of CAPD patients to 1,25 dihydroxyvitamin D3.Kidney Int1990; 37: 1310–5.
10.
BrunkhorstR., WrenglerE., SchindlerR.Peritoneal mononuclear cell (MNC) cytokine production in nightly intermittent peritoneal dialysis (NIPD). Abstracts of XXIXth congress of the European Dialysis and Transplant Association-European Renal Association, 1992: 149.
11.
VlaanderenK., BosH.J., DefijterC.W.H.Short dwell times reduce the local defense mechanism of chronic peritoneal dialysis patients.Nephron1991; 57: 29–35.
12.
Diaz-BuxoJ.A.Does CCPD lower the peritonitis rate?Contrib Nephrol1987; 57: 191–6.
13.
Continuous ambulatory peritoneal dialysis in the USA.Developments in nephrology, vo123. In: LindbladA.S., NolphK.D., eds. In Dordrecht: Kluwer Academic, 1989.
14.
TopleyN., AlobaidiH.M.M., DaviesM.The effect of dialysate on peritoneal phagocyte oxidative metabolism.Kidney Int1988; 34: 404–11.
15.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
16.
JorresA., Jon-EsD., GahlG.Leukotriene B4 and tumor necrosis factor release from leukocytes: Effect of peritoneal dialysate.Nephron1991; 58: 276–82.
17.
TopleyN., MackenzieR., PetersenM.M.In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid.Nephrol Dial Transplant1991; 6: 574–81.
18.
LiberekT., TopleyN., MistryC.D.Cell function and viability in glucose polymer peritoneal dialysis fluids.Peril Dial Int, 1993; 13: 104–11.
19.
De FijterC.W.H., VerbrughH.A., OeP.L.The effect of glycerol-containing peritoneal dialysis fluid on peritoneal macrophage function in vivo. In: KhannaR., NolphK.D., ProwantB.., eds. Advances in continuous ambulatory peritoneal dialysis.Peritoneal Dialysis Bulletin. 1991: 154–7.
20.
HolmesC.J., KubeyW., AonoF.In vitro effect of an amino acid-based peritoneal dialysis fluid on human leukocyte function and receptor expression.J Am Soc Nephrol1992; 3(3): 412.
21.
JorresGah1 G.M., LudatK.In vitro biocompatibility testing of a new bicarbonate-buffered dialysis fluid for CAPD.Perit Diallnt1992; 12(Suppl 2): 26.
22.
PirainoB., BemardiniB.S.N., HolleyJ.L.Increased risk of Staphylococcus epidermidis peritonitis in patients on dialysate containing 1.25 mmol/L calcium.Am J Kidney Dis1992; 4: 371–4.
23.
HutchinsonA.J., TurnerK., GokalR.Effect of long-term therapy with 1.25 mmol/L calcium peritoneal dialysis fluid on the incidence of peritonitis in CAPD.Perit Dial Int1992; 12: 321–5.
24.
GuiberteauR., Le ChapoisD., NonyA.Treatment of peritoneal infection by the natural defenses of the peritoneal cavity.Contrib Nephrol1987; 57: 92–100.
25.
PagniezD.C., MacNamaraE., FortinF.Withdrawal of continuous ambulatory peritoneal dialysis to treat mild peritonitis.Br Med J1988; 297: 1174–5.
26.
CairnsH.S., BeckettJ., RudgeE.J.Treatment of resistant CAPD peritonitis by temporary discontinuation of peritoneal dialysis.Clin Nephrol1989; 32: 2730.
27.
YoungG.A., KoppleJ.D., LindholmB.Nutritional assessment of continuous ambulatory peritoneal dialysis patients: An international study.Am J Kidney Dis1991; 4: 462–71.
28.
YoungG.A., YoungJ.B., YoungS.M.Nutrition and delayed hypersensitivity during continuous ambulatory peritoneal dialysis in relation to peritonitis.Nephron1986; 43: 177–86.
29.
BlakeP.G., SombolosG.A., WeissgartenJ.Lack of con-elation between urea kinetics indices and clinical outcomes in CAPD patients.Kidney Int1991; 39: 700–6.
30.
ChurchillD.N.Adequacy of peritoneal dialysis and other outcome-related risk factors: A critical appraisal.Semin Dial1992; 5(2): 142–6.
